BIAF

bioAffinity is a pre-scale diagnostics company whose entire investable thesis rests on one product, CyPath Lung, which grew 87% to just $963,000 in FY2025. Everything around that is deteriorating. Consolidated revenue fell 34% to $6.16M as management deliberately discontinued 'unprofitable pathology services,' and the net loss widened 65% to -$14.9M. Gross margin is essentially zero, operating margin is -171.6% and net margin -242%. This is not a business generating returns — accumulated deficit stands at -$68.6M against just $7.28M of equity, and ROE is -204.9%. The 0.6x P/S looks optically cheap, but it is being applied to shrinking, near-zero-margin revenue, so it signals distress, not value.

The balance sheet is the crux. Cash improved to $6.45M, but only because the company raised ~$16.9M of gross equity proceeds during the year. Operating cash flow was -$9.33M, meaning the current cash pile funds well under a year of burn at the FY2025 rate — this company must return to the market to survive, and the FY2025 history (retroactive 1-for-30 reverse split on Sept 18, 2025, followed by a $2.50 registered direct offering) shows what that looks like for holders: repeated, deeply dilutive raises. The 75% drop in reported share count is a reverse-split artifact, not deleveraging.